AU2002320325B2 - SIR2 activity - Google Patents

SIR2 activity Download PDF

Info

Publication number
AU2002320325B2
AU2002320325B2 AU2002320325A AU2002320325A AU2002320325B2 AU 2002320325 B2 AU2002320325 B2 AU 2002320325B2 AU 2002320325 A AU2002320325 A AU 2002320325A AU 2002320325 A AU2002320325 A AU 2002320325A AU 2002320325 B2 AU2002320325 B2 AU 2002320325B2
Authority
AU
Australia
Prior art keywords
sir2
cell
cells
protein
transcription factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002320325A
Other languages
English (en)
Other versions
AU2002320325A1 (en
AU2002320325A2 (en
Inventor
Leonard Guarente
Shin-Ichiro Imai
Homayoun Vaziri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Original Assignee
Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology filed Critical Whitehead Institute for Biomedical Research
Publication of AU2002320325A2 publication Critical patent/AU2002320325A2/en
Publication of AU2002320325A1 publication Critical patent/AU2002320325A1/en
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Application granted granted Critical
Publication of AU2002320325B2 publication Critical patent/AU2002320325B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002320325A 2001-07-06 2002-07-08 SIR2 activity Ceased AU2002320325B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30337001P 2001-07-06 2001-07-06
US30345601P 2001-07-06 2001-07-06
US60/303,370 2001-07-06
US60/303,456 2001-07-06
US19015902A 2002-07-05 2002-07-05
US10/190,159 2002-07-05
PCT/US2002/021461 WO2003004621A2 (fr) 2001-07-06 2002-07-08 Activite de sir2

Publications (3)

Publication Number Publication Date
AU2002320325A2 AU2002320325A2 (en) 2003-01-21
AU2002320325A1 AU2002320325A1 (en) 2003-05-22
AU2002320325B2 true AU2002320325B2 (en) 2008-04-03

Family

ID=32074257

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320325A Ceased AU2002320325B2 (en) 2001-07-06 2002-07-08 SIR2 activity

Country Status (4)

Country Link
EP (1) EP1529115A4 (fr)
AU (1) AU2002320325B2 (fr)
CA (1) CA2453195A1 (fr)
WO (1) WO2003004621A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
WO2003046207A2 (fr) 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Procedes d'inhibition de l'activite deacetylase
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
DE60335875D1 (de) 2002-05-23 2011-03-10 Univ California Verfahren zum Auswählen von Modulatoren der mitochondrialen NAD-abhängigen Deacetylase, SIRT3
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Muth, V. et al. EMBO (European Molecular Biology Organisation), March 2001. Vol.20, No.6, pg1353-1362 *

Also Published As

Publication number Publication date
WO2003004621A3 (fr) 2005-03-17
WO2003004621A2 (fr) 2003-01-16
EP1529115A2 (fr) 2005-05-11
EP1529115A4 (fr) 2005-08-24
CA2453195A1 (fr) 2003-01-16
AU2002320325A2 (en) 2003-01-21

Similar Documents

Publication Publication Date Title
US8546074B2 (en) Sir2 activity
US20040005574A1 (en) SIR2 activity
Sasaki et al. Filamin associates with Smads and regulates transforming growth factor-β signaling
Olsson et al. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
US20050136429A1 (en) SIRT1 modulation of adipogenesis and adipose function
US20080119434A1 (en) Sir2a-based therapeutic and prophylactic methods
JP2008529502A (ja) 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物
Davé et al. Nuclear factor of activated T cells regulates transcription of the surfactant protein D gene (Sftpd) via direct interaction with thyroid transcription factor-1 in lung epithelial cells
JP2006515163A (ja) Ｘｂｐ−１活性を調整するための方法および組成物
Xie et al. The proteasome activator REGγ accelerates cardiac hypertrophy by declining PP2Acα–SOD2 pathway
Mercy et al. Mitochondrial biogenesis in mtDNA‐depleted cells involves a Ca2+‐dependent pathway and a reduced mitochondrial protein import
US7771961B2 (en) Cytochrome c acetylation
AU2002320325B2 (en) SIR2 activity
Wang et al. EWSR1 regulates mitosis by dynamically influencing microtubule acetylation
AU2002320325A1 (en) SIR2 activity
Ghosh et al. Fibroblasts derived from patients with opsismodysplasia display SHIP2‐specific cell migration and adhesion defects
Narayan et al. Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties
Homayouni et al. Interaction of Disabled-1 and the GTPase activating protein Dab2IP in mouse brain
Lee et al. The transcription factor STAT2 enhances proteasomal degradation of RCAN1 through the ubiquitin E3 ligase FBW7
Wu et al. CD45 recruits adapter protein DOK-1 and negatively regulates JAK–STAT signaling in hematopoietic cells
Capanni et al. Emerin—prelamin A interplay in human fibroblasts
CA2519161A1 (fr) Activite de sir2
US9541546B2 (en) Method of promoting excitatory synapse formation with an anti-Ephexin5 phospho-Y361 antibody
Khanna Regulation of the cyclin-dependent kinase inhibitor, p21WAF-1, by the v-Abl protein tyrosine kinase, a potent suppressor of apoptosis
US20070173472A1 (en) Methods and reagents for the treatment of apoptosis-related disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE CO-INVENTOR GU, WEI

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE CO-APPLICANT ELIXIR PHARMACEUTICALS, INC. ADD CO-APPLICANTS WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH; MASSACHUSETTS INSTITUTE OF TECHNOLOGY

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAY 2005

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired